Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28691434)

Published in J Int AIDS Soc on June 27, 2017

Authors

Linda Barlow-Mosha1, Victor Musiime2,3, Mary-Ann Davies4, Andrew J Prendergast5,6,7, Philippa Musoke1,2, George Siberry8, Martina Penazzato9

Author Affiliations

1: Clinic Department, Makerere University John Hopkins University (MUJHU) Research Collaboration, Kampala, Uganda​.
2: Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda.
3: Research Department, Joint Clinical Research Centre, Kampala, Uganda​.
4: School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
5: Blizard Institute, Queen Mary University of London, UK.
6: Research Department, Zvitambo Institute for Maternal and Child Health Research, Harare, Zimbabwe​.
7: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
8: Maternal and Pediatric Infectious Disease Branch, National Institutes of Health, Bethesda, MD, USA.
9: HIV Department, World Health Organization, Geneva, Switzerland​.

Articles cited by this

Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med (2008) 17.12

Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet (2004) 16.28

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med (2007) 6.26

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med (2015) 5.30

Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46

Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41

AIDS among older children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic. AIDS (2009) 2.92

Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. Lancet Infect Dis (2014) 2.44

Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01

Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS (2014) 1.91

Chronic lung disease in adolescents with delayed diagnosis of vertically acquired HIV infection. Clin Infect Dis (2012) 1.90

Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90

Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland. J Acquir Immune Defic Syndr (2008) 1.75

Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics (1997) 1.70

Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr (2010) 1.51

Neurodevelopment in perinatally HIV-infected children: a concern for adolescence. J Int AIDS Soc (2013) 1.46

Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries. Pediatrics (2011) 1.41

Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics (2012) 1.40

Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. Pediatr Infect Dis J (2009) 1.32

Sexual risk reduction needs of adolescents living with HIV in a clinical care setting. AIDS Care (2008) 1.30

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. PLoS Med (2013) 1.19

Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis (2013) 1.16

Younger age at HAART initiation is associated with more rapid growth reconstitution. AIDS (2011) 1.15

Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study. JAMA Pediatr (2013) 1.15

Adolescent HIV--cause for concern in Southern Africa. PLoS Med (2010) 1.14

Heart disease among children with HIV/AIDS attending the paediatric infectious disease clinic at Mulago Hospital. Afr Health Sci (2005) 1.13

Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. J Int AIDS Soc (2012) 1.13

The Lablite project: a cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe. BMC Health Serv Res (2014) 1.08

Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr (2012) 1.07

Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. AIDS Res Hum Retroviruses (2013) 1.03

Persistent and chronic lung disease in HIV-1 infected and uninfected African children. AIDS (1998) 1.01

Growth velocity, fat-free mass and energy intake are inversely related to viral load in HIV-infected children. J Nutr (2000) 1.01

Growth, survival and viral load in symptomatic childhood human immunodeficiency virus infection. Pediatr Infect Dis J (2003) 1.01

Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. J Antimicrob Chemother (2008) 1.01

Cardiovascular dysfunction in HIV-infected children in a sub-Saharan African country: comparative cross-sectional observational study. J Trop Pediatr (2011) 1.01

Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother (2012) 1.00

Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. AIDS (2013) 0.95

Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Pediatr Infect Dis J (2010) 0.92

Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. Pediatr Infect Dis J (2015) 0.91

When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. PLoS Med (2013) 0.89

Prevalence of lipodystrophy in HIV-infected children in Tanzania on highly active antiretroviral therapy. Pediatr Infect Dis J (2013) 0.89

Impact of the antiretroviral treatment program on the burden of hospitalization for culture-confirmed tuberculosis in South African children: a time-series analysis. Pediatr Infect Dis J (2013) 0.88

Effect of Age at Antiretroviral Therapy Initiation on Catch-up Growth Within the First 24 Months Among HIV-infected Children in the IeDEA West African Pediatric Cohort. Pediatr Infect Dis J (2015) 0.88

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. Int J Epidemiol (2016) 0.87

Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda. AIDS Res Hum Retroviruses (2012) 0.86

Neurodevelopmental benefits of antiretroviral therapy in Ugandan children aged 0-6 years with HIV. J Acquir Immune Defic Syndr (2014) 0.85

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. Pediatr Infect Dis J (2015) 0.83

Cardiac findings in children admitted to a hospital general ward in South Africa: a comparison of HIV-infected and uninfected children. Cardiovasc J S Afr (2005) 0.83

HIV-related bronchiectasis in children: an emerging spectre in high tuberculosis burden areas. Int J Tuberc Lung Dis (2012) 0.83

Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults. BMC Infect Dis (2015) 0.83

Long-term nonprogression of HIV infection in children: evaluation of the ANRS prospective French Pediatric Cohort. Clin Infect Dis (2007) 0.83

The challenge of chronic lung disease in HIV-infected children and adolescents. J Int AIDS Soc (2013) 0.82

Pubertal development in HIV-infected African children on first-line antiretroviral therapy. AIDS (2015) 0.82

Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy. AIDS Res Hum Retroviruses (2013) 0.80

Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children. AIDS (2014) 0.80

The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children. J Int AIDS Soc (2015) 0.79

Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy. J Pediatr Endocrinol Metab (2014) 0.78